Zentalis FY2024 cash $371.1M; azenosertib 34.9% ORR in PROC; cash runway to late 2027

Zentalis Pharmaceuticals, Inc.

Cash $371.1M; projected runway to late 2027. FY2024 op expenses $258.6M, down from $299.5M.
Azenosertib monotherapy 34.9% ORR (n=43) in Cyclin E1+ PROC from DENALI Part 1b; mDOR 6.3 months.
FDA Fast Track for azenosertib in PROC. DENALI Part 2 enrollment H1 2025, topline data by end 2026.
New CEO Julie Eastland, CMO Ingmar Bruns, and other executives appointed in Nov 2024.
Jan 2025 strategic restructuring to reduce costs; workforce reduction substantially complete Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.